{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:30:26Z","timestamp":1767900626434,"version":"3.49.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"DOI":"10.7759\/cureus.101086","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:50:12Z","timestamp":1767883812000},"source":"Crossref","is-referenced-by-count":0,"title":["Nemolizumab as an Alternative Therapeutic Option for Indolent Systemic Mastocytosis"],"prefix":"10.7759","author":[{"given":"Sezim","family":"Minbaeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani A","year":"2023","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management. Am J Hematol. 2023, 98:1097-116. 10.1002\/ajh.26962","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06475-y","article-title":"The evaluation, management, and future of indolent systemic mastocytosis","volume":"104","author":"Syal A","year":"2025","unstructured":"Syal A, Toh J, McInerney A, Tremblay D. The evaluation, management, and future of indolent systemic mastocytosis. Ann Hematol. 2025, 104:3917-27. 10.1007\/s00277-025-06475-y","journal-title":"Ann Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10498-3","article-title":"Comprehensive mastocytosis data analysis from a single center","volume":"23","author":"Tiryaki TO","year":"2023","unstructured":"Tiryaki TO, \u00d6zkan SG, Erdem S, et al.. Comprehensive mastocytosis data analysis from a single center. BMC Cancer. 2023, 23:82. 10.1186\/s12885-022-10498-3","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.039","article-title":"Mastocytosis: part i: pathogenesis, clinical presentation and classification","volume":"4","author":"Sizemore JA","year":"2025","unstructured":"Sizemore JA, Hansen S, Moran CA, Petty AJ, Rein LA, Jamison MO, Nicholas MW. Mastocytosis: part i: pathogenesis, clinical presentation and classification. J Am Acad Dermatol. 2025, 4:4-6. 10.1016\/j.jaad.2025.06.039","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0030","article-title":"NCCN Guidelines\u00ae Insights: Systemic Mastocytosis, Version 3.2024","volume":"22","author":"Gotlib J","year":"2024","unstructured":"Gotlib J, Gerds AT, Abdelmessieh P, et al.. NCCN Guidelines\u00ae Insights: Systemic Mastocytosis, Version 3.2024. J Natl Compr Canc Netw. 2024, 22:14-6. 10.6004\/jnccn.2024.0030","journal-title":"J Natl Compr Canc Netw"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima K","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020, 383:141-50. 10.1056\/NEJMoa1917006","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra SG","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, et al.. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023, 389:1579-89. 10.1056\/NEJMoa2301333","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg JI","year":"2024","unstructured":"Silverberg JI, Wollenberg A, Reich A, et al.. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024, 404:445-60. 10.1016\/S0140-6736(24)01203-0","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445060-nemolizumab-as-an-alternative-therapeutic-option-for-indolent-systemic-mastocytosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T14:50:13Z","timestamp":1767883813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445060-nemolizumab-as-an-alternative-therapeutic-option-for-indolent-systemic-mastocytosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.101086","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}